# Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.

> **NCT03602547** · PHASE2 · UNKNOWN · sponsor: **AnewPharma** · enrollment: 40 (estimated)

## Conditions studied

- Mucosal Melanoma

## Interventions

- **DRUG:** CM082 plus JS001

## Key facts

- **NCT ID:** NCT03602547
- **Lead sponsor:** AnewPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-31
- **Primary completion:** 2019-07
- **Final completion:** 2020-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03602547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03602547, "Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03602547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*